Melanoma Update 2016


Related Videos (117)

Lynn M Schuchter, MD, Chief of the Division of Hematology Oncology at Penn Medicine, has been treating patients with melanoma for three decades. In this presentation, she reviews recent clinical trials to conclude that the developments of the last decade, including the anti-PD-1 agents, the anti-CTLA4 agents and the anti-BRAF and anti-MEK inhibitors have vastly improved the outlook for patients with melanoma, extending the 2-year overall survival from 24% in 2010 to 64% (with nivolumab+ ipilimumab) in 2016.


Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®